Wugen has completed USD 115 million financing led by Fidelity Management & Research Company to advance its allogeneic CAR-T therapy WU-CART-007 for T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL). The CRISPR-edited CD7-targeted therapy achieved 91% overall response rate and 73% complete response rate (CRR) in Phase I/II trials, with median response duration exceeding six months. The funding supports ongoing pivotal T-RRex study and commercial manufacturing preparation for anticipated 2027 biologics license application submission.

WU-CART-007 holds regenerative medicine advanced therapy, fast track and orphan drug designations (ODD) in the US, plus PRIME status from the European Medicines Agency (EMA). The therapy eliminates CD7 and T-cell receptor expression to prevent CAR-T cell fratricide and graft-versus-host disease, positioning it as the first off-the-shelf CAR-T for T-cell malignancies. Wugen's platform extends beyond oncology to autoimmune applications leveraging its allogeneic cell engineering capabilities.

According to PharmCube's NextBiopharm® database, Wugen's portfolio focuses on cell therapies. Click here to request a free trial for NextBiopharm®.